The Manufacturers Life Insurance Company Has $87,000 Stock Position in Organogenesis Holdings Inc. (NASDAQ:ORGO)

The Manufacturers Life Insurance Company raised its holdings in Organogenesis Holdings Inc. (NASDAQ:ORGO) by 15.4% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 30,984 shares of the company’s stock after buying an additional 4,130 shares during the quarter. The Manufacturers Life Insurance Company’s holdings in Organogenesis were worth $87,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Los Angeles Capital Management LLC lifted its position in shares of Organogenesis by 45.9% during the 1st quarter. Los Angeles Capital Management LLC now owns 500,567 shares of the company’s stock valued at $1,422,000 after acquiring an additional 157,575 shares during the period. Denali Advisors LLC acquired a new position in shares of Organogenesis during the first quarter valued at about $129,000. Principal Financial Group Inc. acquired a new position in shares of Organogenesis during the first quarter valued at about $100,000. BNP Paribas Financial Markets boosted its position in shares of Organogenesis by 573.9% during the 1st quarter. BNP Paribas Financial Markets now owns 123,386 shares of the company’s stock worth $350,000 after purchasing an additional 105,078 shares in the last quarter. Finally, GSA Capital Partners LLP grew its stake in shares of Organogenesis by 102.8% in the 1st quarter. GSA Capital Partners LLP now owns 531,218 shares of the company’s stock valued at $1,509,000 after buying an additional 269,315 shares during the period. 49.57% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Separately, Lake Street Capital initiated coverage on Organogenesis in a report on Friday, June 28th. They issued a “buy” rating and a $5.00 price target on the stock.

Organogenesis Stock Performance

ORGO opened at $3.16 on Monday. Organogenesis Holdings Inc. has a 1-year low of $1.96 and a 1-year high of $4.70. The company has a market cap of $418.92 million, a price-to-earnings ratio of -24.31 and a beta of 1.60. The company’s fifty day moving average price is $2.83 and its two-hundred day moving average price is $2.77. The company has a current ratio of 2.73, a quick ratio of 2.42 and a debt-to-equity ratio of 0.22.

Organogenesis (NASDAQ:ORGO) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.02) by ($0.11). The business had revenue of $130.23 million during the quarter, compared to the consensus estimate of $122.48 million. Organogenesis had a negative net margin of 3.69% and a negative return on equity of 6.03%. On average, analysts expect that Organogenesis Holdings Inc. will post -0.17 EPS for the current fiscal year.

About Organogenesis

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.